{
  "id": "34a709b46c303daa",
  "title": "FDA Accepts LEQEMBI\u00ae IQLIKTM ( lecanemab - irmb ) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer Disease under Priority Review",
  "description": "20260211T111500Z",
  "content": "",
  "source": "berkshireeagle.com",
  "source_url": "https://www.berkshireeagle.com/online_features/press_releases/fda-accepts-leqembi-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose/article_0eba5878-6616-5afd-9a23-3260335bbc20.html",
  "published_at": "20260211T111500Z",
  "fetched_at": "2026-02-12T00:28:38.246764+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.berkshireeagle.com/online_features/press_releases/fda-accepts-leqembi-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose/article_0eba5878-6616-5afd-9a23-3260335bbc20.html",
    "url_mobile": "",
    "title": "FDA Accepts LEQEMBI\u00ae IQLIKTM ( lecanemab - irmb ) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer Disease under Priority Review",
    "seendate": "20260211T111500Z",
    "socialimage": "https://bloximages.newyork1.vip.townnews.com/berkshireeagle.com/content/tncms/assets/v3/editorial/a/57/a570464c-ae04-5c43-9954-5ff39a8f5627/69771955479ef.image.jpg?crop=224%2C224%2C288%2C0",
    "domain": "berkshireeagle.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}